HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Tranexamic acid may be a useful pharmacotherapy for endoscopically resistant small bowel angiodysplasia.

Abstract
Small bowel angiodysplasia (SBAD) is reported to account for nearly 50% of cases of small bowel bleeding. When SBAD occurs frequently, it is difficult to treat all the angiodysplasias endoscopically, and gastrointestinal bleeding often recurs. Hormone therapy, somatostatin analogs, thalidomide and vascular endothelial growth factor (VEGF)-neutralizing antibodies have been reported to reduce gastrointestinal angiodysplasia (GIAD) bleeding. However, there is no strong evidence to recommend them. Also, there are no guidelines for their use. Hereditary hemorrhagic telangiectasia (HHT) is a hereditary disease caused by abnormalities in VEGF, resulting in multiple GIADs. A treatment guideline has been created for GIAD in HHT, and the use of tranexamic acid, an antifibrinolytic agent, is the first recommendation pharmacotherapy for GIAD with gastrointestinal bleeding that is difficult to treat endoscopically. It has been reported that fibrinolysis is accelerated in GIAD patients who are not HHT, similar to HHT patients. The use of tranexamic acid for gastric antral vascular ectasia in GIAD has been reported to be useful. However, there are very few reports of its use for SBAD. There are concerns with tranexamic acid use regarding the development of thrombosis/embolism, but there are few reports of such side effects. Future clinical trials including tranexamic acid for SBAD are desired.
AuthorsShunji Fujimori
JournalWorld journal of gastroenterology (World J Gastroenterol) Vol. 29 Issue 7 Pg. 1131-1138 (Feb 21 2023) ISSN: 2219-2840 [Electronic] United States
PMID36926669 (Publication Type: Journal Article, Review)
Copyright©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Chemical References
  • Tranexamic Acid
  • Vascular Endothelial Growth Factor A
Topics
  • Humans
  • Tranexamic Acid (adverse effects)
  • Vascular Endothelial Growth Factor A
  • Gastrointestinal Hemorrhage (drug therapy, etiology)
  • Colonic Diseases
  • Angiodysplasia (complications, diagnosis, drug therapy)
  • Telangiectasia, Hereditary Hemorrhagic (complications, drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: